Goldman, Citi Among 22 Banks On CD&R’s Buyout Of Sanofi Unit

Banks are eager to return to funding leveraged buyouts after the first Federal Reserve interest rate cut in four years raised hopes that debt costs are finally starting to ease.

Banks are eager to return to funding leveraged buyouts after the first Federal Reserve interest rate cut in four years. (Photographer: Nathan Laine/Bloomberg)

(Bloomberg) --Goldman Sachs Group Inc and Citigroup Inc. are among 22 banks set to provide Clayton Dubilier & Rice with buyout financing for a stake in Sanofi SA’s consumer health division.

Lenders are expected to sign on to the deal to provide €8.65 billion ($9.4 billion) of euro- and dollar-denominated loan and bond financing in the coming days, according to people familiar with the deal, who asked not to be identified discussing private matters.

Seven lenders, including Barclays Plc, BNP Paribas SA, Citigroup Inc., Goldman Sachs Group Inc, Morgan Stanley and Societe Generale SA, are expected to act as global co-ordinators, the people said. The share of the global coordinators’ fees is expected to be in the high single digits, and the shares of the 15 or so other banks will be in the low single digits, one of the people said.

Banks are eager to return to funding leveraged buyouts after the first Federal Reserve interest rate cut in four years raised hopes that debt costs are finally starting to ease. Such deals are some of the most lucrative operations in finance and the Sanofi buyout is one of the biggest in Europe so far this year.

Citi was advising CD&R on the sale, while Goldman Sachs and Morgan Stanley were sellside advisors. JPMorgan Chase & Co. advised France’s PAI Partners on a rival bid. It’s unclear whether the Wall Street giant will be among lenders financing the CD&R deal.

Representatives from Citi, Goldman Sachs, Societe Generale, BNP Paribas, JPMorgan, Morgan Stanley and CD&R declined to comment. Sanofi referred all questions to CD&R. A spokesperson for Barclays didn’t immediately respond to a request for comment.

Also Read: Sanofi Consumer Healthcare: Promoter Hoechst Exits Firm, Sells Stake Worth Rs 6,927 Crore To Opella Healthcare

Fee squeeze

Each bank is receiving a lower share of the fee than would usually be expected in a deal of this size because the deal is being split 22 ways, an unusually large number. Sponsors are coming coming under pressure to gift roles to as many banks as possible due to the lack of recent large M&A deals.

Global coordinators tend to take a leading role in the sell down of debt to institutional investors, entitling them to more fees. Up to four of the seven banks could take charge of the euro term loan, while other global coordinators could take a solo spot leading the sell down of the rest, the people said.

Banks have signed funding commitments for a €5.45 billion term loan B split between euros and dollars, with target pricing of 350 basis points over Euribor for the euro component, and 325 basis points over SOFR for the US dollar tranche, Bloomberg previously reported.

There is also a €2 billion bridge to high-yield bond financing, with caps of 7.5% for the euro bonds and 8.5% for the dollars. Banks will also give around €1.2 billion of revolving credit facility.

CD&R will not be using the more than €1 billion of so-called back leverage that banks had lined up to help fund the equity check, as reported by Bloomberg. That’s because it has secured a more than €1 billion payment-in-kind loan from private credit funds, the people said.

Also Read: Panacea Biotec Hits Highest Level In Over Three Years As Company Settles Patent Dispute With Sanofi

Watch LIVE TV , Get Stock Market Updates, Top Business , IPO and Latest News on NDTV Profit.
GET REGULAR UPDATES